Collegium Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Collegium Pharmaceutical has been growing earnings at an average annual rate of 16.1%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 14.4% per year. Collegium Pharmaceutical's return on equity is 24.6%, and it has net margins of 8.5%.
Key information
16.1%
Earnings growth rate
16.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 14.4% |
Return on equity | 24.6% |
Net Margin | 8.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Collegium Pharmaceutical: Thoughts After Another Strategic Move
Feb 20There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding
Feb 15We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Oct 30Sizing Up Collegium Pharmaceuticals
Oct 04Collegium Pharmaceutical: Moving Closer To The Top
Jul 12Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment
May 14Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings
May 13We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt
May 01Revenue & Expenses BreakdownBeta
How Collegium Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 567 | 48 | 151 | 0 |
30 Sep 23 | 547 | 9 | 187 | 0 |
30 Jun 23 | 537 | -11 | 190 | 0 |
31 Mar 23 | 525 | -29 | 188 | 0 |
31 Dec 22 | 464 | -25 | 142 | 4 |
30 Sep 22 | 362 | -43 | 127 | 6 |
30 Jun 22 | 314 | -35 | 119 | 7 |
31 Mar 22 | 273 | 43 | 113 | 11 |
31 Dec 21 | 277 | 72 | 119 | 9 |
30 Sep 21 | 326 | 104 | 119 | 10 |
30 Jun 21 | 326 | 107 | 115 | 11 |
31 Mar 21 | 321 | 42 | 114 | 10 |
31 Dec 20 | 310 | 27 | 114 | 10 |
30 Sep 20 | 308 | 18 | 112 | 10 |
30 Jun 20 | 302 | 0 | 116 | 10 |
31 Mar 20 | 299 | -13 | 115 | 10 |
31 Dec 19 | 297 | -23 | 116 | 10 |
30 Sep 19 | 296 | -11 | 122 | 10 |
30 Jun 19 | 293 | -22 | 125 | 10 |
31 Mar 19 | 291 | -30 | 128 | 9 |
31 Dec 18 | 280 | -39 | 127 | 9 |
30 Sep 18 | 218 | -66 | 120 | 9 |
30 Jun 18 | 160 | -62 | 109 | 9 |
31 Mar 18 | 90 | -70 | 100 | 9 |
31 Dec 17 | 28 | -75 | 91 | 9 |
30 Sep 17 | 19 | -85 | 93 | 10 |
30 Jun 17 | 7 | -98 | 94 | 11 |
31 Mar 17 | 4 | -102 | 92 | 13 |
31 Dec 16 | 2 | -94 | 81 | 15 |
30 Sep 16 | 0 | -76 | 63 | 13 |
30 Jun 16 | 0 | -59 | 46 | 13 |
31 Mar 16 | 0 | -40 | 28 | 11 |
31 Dec 15 | 0 | -20 | 19 | 8 |
30 Sep 15 | 0 | -15 | 12 | 9 |
30 Jun 15 | 0 | -13 | 7 | 11 |
31 Mar 15 | 0 | -12 | 4 | 13 |
31 Dec 14 | 0 | -21 | 3 | 15 |
Quality Earnings: COLL has a large one-off loss of $47.1M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: COLL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COLL has become profitable over the past 5 years, growing earnings by 16.1% per year.
Accelerating Growth: COLL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: COLL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: Whilst COLL's Return on Equity (24.64%) is high, this metric is skewed due to their high level of debt.